CCELNYSEServices-Misc Health & Allied Services, NECFiscal year ends November 30

CRYO CELL INTERNATIONAL INC

Financials through Q3 FY2026, quarter ended Aug 31, 2026Last filing: 10-Q on Oct 9, 2026

$4.65+0.23 (+5.20%)

Close on Oct 19, 2026

Market cap: $37.50M
P/E (TTM): –
Dividend yield: –

CRYO CELL INTERNATIONAL INC income statement

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-11-30	FY 2024 2024-11-30	FY 2023 2023-11-30	FY 2022 2022-11-30	FY 2021 2021-11-30	FY 2020 2020-11-30	FY 2019 2019-11-30	FY 2018 2018-11-30	FY 2017 2017-11-30	FY 2016 2016-11-30	FY 2015 2015-11-30	FY 2014 2014-11-30	FY 2013 2013-11-30	FY 2012 2012-11-30	FY 2011 2011-11-30	FY 2010 2010-11-30
Revenue	32	32	31	30	29	31	32	29	25	23	21	20	19	18	18	18
Cost of Revenue	7.38	7.95	8.39	8.79	8.99	9.66	10	8.54	6.72	5.77	5.63	5.63	5.32	4.89	4.40	4.50
Gross Profit	24	24	23	22	20	21	22	21	19	17	15	14	14	13	14	13
Research & Development	0.38	1.24	1.17	0.38	0.05	0.02	0.03	0.09	0.04	0.05	0.05	0.06	0.04	0.11	0.18	0.13
Selling, General & Admin	18	19	17	16	15	14	15	16	13	15	12	12	11	14	12	9.49
Advertising Expenses	1.09	1.07	0.95	0.76	0.84	0.85	0.98	0.99	1.01	1.19	0.76	0.62	0.62	0.69	2.20	–
Total Costs & Expenses	31	29	44	26	25	23	27	24	20	23	18	18	17	20	18	14
Operating Income	0.48	3.48	-12	4.02	4.02	7.66	5.06	5.19	5.01	0.43	2.93	1.98	1.70	-1.71	-0.28	3.35
Interest Expense	2.07	1.86	1.24	1.52	1.38	1.54	1.70	1.55	1.30	0.95	1.30	1.15	1.40	1.02	1.46	1.28
Interest & Investment Income	–	–	–	–	–	–	–	–	–	–	–	–	–	0.06	0.04	0.03
Income from Equity Investments	–	–	–	–	–	–	–	–	–	–	-0.02	-0.36	-0.15	-0.15	-0.23	-0.18
Other Non-Operating Income	-2.82	-0.68	-1.06	-0.71	-1.41	-2.62	-1.67	-1.57	-1.38	-2.91	-1.96	-0.94	-1.35	-2.55	-1.42	-1.26
Asset Impairment Charges	–	0	0	0	0	0	0	0	0	1.99	0	0	0	0	0.63	–
Gain (Loss) on Sale of Assets	-0.05	0	0	0.41	-0.02	0.00	–	-0.16	–	–	–	–	-0.04	–	-0.02	–
Pretax Income	-2.34	2.80	-13	3.32	2.61	5.04	3.39	3.62	3.62	-2.48	0.95	0.68	0.20	-4.42	-1.92	1.90
Income Tax Expense	0.09	2.40	-3.84	0.55	0.53	1.41	1.10	4.47	1.31	-1.16	-7.16	0.12	0.17	1.89	0.17	-1.56
Net Income incl. Noncontrolling Interests	-2.43	0.40	-9.52	2.77	2.08	3.62	2.29	-0.85	2.32	–	–	–	–	–	–	–
Net Income	-2.43	0.40	-9.52	2.77	2.08	3.62	2.29	-0.85	2.32	-1.32	8.11	0.55	0.03	-6.31	-2.10	3.46
EPS (Basic)(per share)	-0.30	0.05	-1.14	0.33	0.26	0.48	0.29	-0.11	0.33	-0.16	0.85	0.05	0.00	-0.56	-0.18	0.29
EPS (Diluted)(per share)	-0.30	0.05	-1.14	0.33	0.25	0.45	0.27	-0.11	0.30	-0.16	0.83	0.05	0.00	-0.56	-0.18	0.29
Shares Outstanding (Basic, Weighted)(shares)	8.07	8.13	8.34	8.47	8.14	7.54	7.79	7.46	7.06	8.11	9.54	10	11	11	12	12
Shares Outstanding (Diluted, Weighted)(shares)	8.07	8.21	8.34	8.48	8.36	8.14	8.41	7.46	7.65	8.11	9.80	10	11	11	12	12
Dividend per Share(per share)	–	0.25	–	0.90	–	–	–	–	–	–	–	–	–	–	–	–
EBITDA	1.47	4.17	-11	5.52	5.06	8.03	5.46	5.51	5.14	0.59	3.03	2.15	1.89	-1.51	0.08	3.64

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Aug 31, 2026

Profitability, TTM

Gross margin: 78.5%
Operating margin: 0.6%
Net margin: -6.2%
Return on equity, FY2025: 15.3%

Financial strength

Current ratio: 0.86
Debt to equity: -0.49
Debt to assets: 12.9%
Cash to current liabilities: 9.3%

Valuation

P/E ratio: –
Price to sales: 1.20
Price to book: –
Dividend yield: –